CN1313094C - Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 - Google Patents

Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 Download PDF

Info

Publication number
CN1313094C
CN1313094C CNB038191016A CN03819101A CN1313094C CN 1313094 C CN1313094 C CN 1313094C CN B038191016 A CNB038191016 A CN B038191016A CN 03819101 A CN03819101 A CN 03819101A CN 1313094 C CN1313094 C CN 1313094C
Authority
CN
China
Prior art keywords
methoxyl group
tumor
ionizing radiation
ether
mms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038191016A
Other languages
English (en)
Chinese (zh)
Other versions
CN1674905A (zh
Inventor
S·R·韦奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1674905A publication Critical patent/CN1674905A/zh
Application granted granted Critical
Publication of CN1313094C publication Critical patent/CN1313094C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038191016A 2002-08-09 2003-08-05 Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 Expired - Fee Related CN1313094C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0218525.4 2002-08-09
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
GB0307560.3 2003-04-02
PCT/GB2003/003388 WO2004014383A1 (en) 2002-08-09 2003-08-05 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Publications (2)

Publication Number Publication Date
CN1674905A CN1674905A (zh) 2005-09-28
CN1313094C true CN1313094C (zh) 2007-05-02

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038191016A Expired - Fee Related CN1313094C (zh) 2002-08-09 2003-08-05 Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途

Country Status (13)

Country Link
US (1) US20050222183A1 (enExample)
EP (1) EP1534287A1 (enExample)
JP (1) JP2006502132A (enExample)
KR (1) KR20050056190A (enExample)
CN (1) CN1313094C (enExample)
AU (1) AU2003249000B2 (enExample)
BR (1) BR0313116A (enExample)
CA (1) CA2495487A1 (enExample)
IL (1) IL166522A0 (enExample)
MX (1) MXPA05001458A (enExample)
NO (1) NO20050450L (enExample)
NZ (1) NZ537753A (enExample)
WO (1) WO2004014383A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397401A (zh) * 2016-08-30 2017-02-15 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
CN1240688C (zh) 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US7462623B2 (en) 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US20060167027A1 (en) * 2003-07-10 2006-07-27 Wedge Stephen R Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
ES2399768T3 (es) * 2006-09-29 2013-04-03 Astrazeneca Ab Combinación de ZD6474 y bevacizumab para terapia del cáncer
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397401A (zh) * 2016-08-30 2017-02-15 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Also Published As

Publication number Publication date
NO20050450L (no) 2005-05-02
EP1534287A1 (en) 2005-06-01
KR20050056190A (ko) 2005-06-14
MXPA05001458A (es) 2005-06-06
CA2495487A1 (en) 2004-02-19
NZ537753A (en) 2008-04-30
WO2004014383A1 (en) 2004-02-19
BR0313116A (pt) 2005-07-05
IL166522A0 (en) 2006-01-15
AU2003249000A1 (en) 2004-02-25
AU2003249000B2 (en) 2007-04-05
JP2006502132A (ja) 2006-01-19
US20050222183A1 (en) 2005-10-06
CN1674905A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
CN1313094C (zh) Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途
CN1298328C (zh) 包括应用zd6474和紫杉烷的联合疗法
CN1177833C (zh) 取代的间二氮杂萘衍生物
CN1101392C (zh) 抑制法呢基蛋白质转移酶的(咪唑－5－基)甲基－2－喹啉酮衍生物
CN1155600C (zh) 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂
JP5662564B2 (ja) アリールアミノプリン誘導体、その調製方法および医薬としての使用
CN1116288C (zh) 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
EP3153169B1 (en) Method for treating tumour, pharmaceutical composition and medicine box kit
CN1308535A (zh) 供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
CN1252800A (zh) 具抑制法呢基转化酶作用的喹唑啉酮类
CN1589264A (zh) 用于治疗恶性肿瘤的方法
JP2020122022A (ja) 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
CN1898232A (zh) 用作抗血管发生剂的喹唑啉衍生物的马来酸盐
DE10042061A1 (de) Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI443095B (zh) 新穎鹽
TW200846330A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
TW202216149A (zh) 用於治療非小細胞肺癌之ｅｇｆｒ ｔｋｉ
CN107137409A (zh) 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
CN111362925A (zh) 一种4-嘧啶甲酰胺类化合物、药物组合物、制备方法及应用
JP2018515540A (ja) 乳癌の予防又は治療用の化合物
Li et al. Inhibitory effect of icaritin on proliferation, migration, and invasion of human nasopharyngeal carcinoma cell CNE2 by regulating STAT3 activation
CN115916210A (zh) 用于预防或治疗与ron突变相关的小细胞肺癌的药物组合物及其使用方法
CN1819831A (zh) 包含azd2171和zd1839的癌症联合治疗
CN1199946C (zh) 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
CN1774248A (zh) 联合治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070502

Termination date: 20100805